Get started
Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

ACXP trade ideas

ACXP irrational dumpOn November 20, 2024, Acurx pharmaceuticals announced that it approved the conversion of a portion of its cash reserves into Bitcoin, up to a maximum of $1 million. Immediately, the stock plunged, reflecting shareholder disapproval of this decision. Since then, Acurx has lost around 58% of its value. To me, this reaction is disproportionate for several reasons: - In its field of expertise, the search for new antibiotics, Acurx is well positioned. Its flagship product, ibezapolstat, is set to enter phase 3 next year, following encouraging phase 2 studies. These demonstrated, in 32 patients, non-inferiority of the compound compared with vancomycin in Clostridium difficile infection. - The company has not diluted its shareholders since it decided to invest in Bitcoin. - Antibiotic resistance is a major issue worldwide. Conclusive Phase 3 results would make ibezapolstat a must-have product worldwide. - The company is currently valued at just $15 million. - The Bitcoin price is quietly holding above $90k, with the potential to rise with the arrival of Trump in the White House. Technically, ACXP seems to have found support at $0.72, with a double bottom that will be confirmed after a clear break of the $1 mark. Next results will be announced on March 13, 2025. Will the market realize that the stock is mispriced? Only time will tell. TL;DR: ACXP falls on non-news. Investors will probably realize the mistake when the next results are announced on March 13, 2025. I'm buying here. Disclaimer: Biotech investments are always extremely risky. This is not investment advice. Always do your own research. Manage your risk accordingly.
NASDAQ:ACXPLong
by BenimBel
1
ACXP - LONG The recent advancements by Acurx Pharmaceuticals, Inc. in the development of ibezapolstat, including the scheduling of an End of Phase 2 (EOP2) meeting with the FDA for late April 2024 and the acquisition of SME designation from the European Medicines Agency (EMA), are bullish indicators for the company and its stakeholders. These milestones are significant as they not only validate the potential of ibezapolstat as a novel treatment for C. difficile Infection (CDI) but also underscore the regulatory progress towards a New Drug Application (NDA) filing. The FDA's agreement to hold an EOP2 meeting suggests a positive view on the data and development plan presented by Acurx, potentially smoothing the path towards Phase 3 trials and eventual market approval. Meanwhile, the SME designation by the EMA provides financial and regulatory support, enhancing Acurx's ability to navigate the complex process of obtaining EU Marketing Authorization. These developments demonstrate Acurx's capability to advance through the regulatory landscape efficiently, promising reduced time to market and a competitive edge in the antibiotics sector, making it an attractive prospect for investors and partners. We are at support for the trading range, 786 retrace confluence with Bottom side LVN, I doubt the market wants to send this stock lower, no aggressive selling as yet at this range. unless there is a need for liquidity for the big boys before sending us higher. Good Luck!
NASDAQ:ACXPLong
by SPYDERMARKET
ACXP cheaper than the public offeringAcurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat and in the second half of 2021. (prnewswire.com)
NASDAQ:ACXPLong
by TopgOptions
$ACXP Quiet but GainingConsidering the IPO within the last months, $ACXP has proven to investor its ability to hold value although its SP is not trading alike. Do not be fooled by the numbers, the company has had prior success with EUA and applications via FDA. Though private during inception, the company seeks to fund its ongoing pipeline with diversity. Their current target product line is antibiotics, and have done well before its IPO. Considering the chart, with no prior data and just fundamentals, I have set the Gann Square and S Line to show its support and resistance. Currently trading on lower avg vol, good news could easily move SP. Good luck all.
NASDAQ:ACXPLong
by mrtnquint